Drug intelligence / Profile preview

Med-Oligo antisense oligonucleotide

Development stage: Unknown
Lead developer: AusperBio
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

Med-Oligo is a proprietary antisense oligonucleotide (ASO) technology platform developed by AusperBio. It is designed to enhance ASO therapeutics through novel design insights and efficient targeted delivery conjugation. The platform is modular, enabling the development of therapies for a broad range of conditions, including viral infections (specifically chronic hepatitis B), metabolic diseases, genetic disorders, and immune-related conditions. The lead candidate utilizing this technology is AHB-137, an unconjugated ASO currently in Phase III clinical trials for the functional cure of chronic hepatitis B. The platform aims to expand into immuno-oncology and muscle diseases.

Brand names: Med-Oligo™
Other names: Med-Oligo

Targets

HBV RNA (Hepatitis B virus RNA)

Beyond the preview

Go deeper on Med-Oligo antisense oligonucleotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Med-Oligo antisense oligonucleotide.

Explore the full profile